News and Trends 2 Sep 2016
Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success
Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]